ERBB2 and breast cancer: In a recent publication by Varkartis et al., it was observed that approximately half of the patients with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer treated with PI3Kα inhibitors developed secondary resistance via the PI3K pathway.